Browse the evidence

GLP-1 receptor agonists (GLP-1RAs) such as liraglutide and semaglutide reduce adipocyte size and promote the browning of white adipose tissue (WAT) by upregulating thermogenic genes (e.g., UCP1) and activating the AMPK/SIRT1 pathway, thereby shifting adipose tissue function from energy storage to energy expenditure.

If you are taking a GLP-1 medication like semaglutide or liraglutide, understand that it is actively remodeling your fat tissue. It shrinks fat cells and activates 'browning' processes that burn energy, which is a key part of why these drugs are effective for long-term metabolic health, beyond just reducing your appetite.

Combining tirzepatide with leptin produces synergistic weight loss and improved metabolic homeostasis in diet-induced obesity models, driven by reduced food intake and increased energy expenditure.

For individuals with obesity who have leptin resistance, adding leptin to tirzepatide treatment may enhance weight loss and metabolic health beyond what tirzepatide achieves alone. This synergy works by reducing food intake and increasing energy expenditure, suggesting that combination therapies targeting multiple hormonal pathways can overcome resistance mechanisms.

GLP-1 receptor agonist therapy is associated with significant gastrointestinal adverse events and weight regain upon discontinuation, limiting its long-term durability compared to surgery.

GLP-1 medications like semaglutide or liraglutide can help you lose 15-25% of your body weight, but you may experience nausea, vomiting, or digestive issues. Crucially, if you stop taking the medication, you are likely to regain the weight. Surgery offers more sustained weight loss and cardiovascular protection, though it involves surgical risks.

Resmetirom (THR-β agonist) improves biopsy-confirmed MASH resolution and fibrosis without causing significant weight loss, acting through a lipid-centric mechanism.

If you have MASH, resmetirom is a daily pill that targets liver fat and inflammation directly. It works even if you don't lose weight, making it a distinct option from weight-loss drugs.

Using GLP-1 receptor agonists for weight loss results in higher social stigma and lower willingness to affiliate compared to losing weight through diet and exercise, and is stigmatized even more than remaining at a higher weight without attempting weight loss.

If you use GLP-1s for weight loss, be aware that you may face significant social judgment, potentially more than if you stayed at your current weight. This stigma stems from perceptions that medication is an 'easy shortcut' compared to diet and exercise. This social penalty can undermine the psychological benefits of weight loss and may discourage continued treatment. It is important to seek support and understand that this stigma is a social bias, not a reflection of your health efforts.

Regaining weight after discontinuing GLP-1 receptor agonists is stigmatized to a similar degree as regaining weight after discontinuing diet and exercise, and both are stigmatized more than maintaining weight loss.

If you regain weight after stopping GLP-1s, you may face social judgment similar to that faced by those who regain weight after dieting. This stigma is not unique to medication users. Recognize that weight regain is a common outcome and does not reflect a lack of character. Focus on sustainable health practices rather than avoiding social judgment.

A unimolecular antibody-peptide conjugate combining GIP receptor antagonism and GLP-1 receptor agonism (AMG 133) produces significant, sustained body weight loss in obese non-human primates when administered via once-weekly subcutaneous injection.

This research identifies AMG 133 as a potent obesity treatment in primates, achieving nearly 17% body weight loss with once-weekly injections. For humans, this suggests a future therapy that is more convenient than daily injections and potentially better tolerated than current single-target GLP-1 drugs, though it is not yet available for clinical use.

Retatrutide, a triple incretin agonist, alleviates adipose tissue fibrosis and dysfunction by reprogramming lipid metabolism and suppressing inflammatory pathways, rather than solely reducing fat mass.

Retatrutide is a potent injectable medication for obesity that works by fundamentally changing how fat tissue functions—reducing inflammation and fibrosis and improving metabolic health—rather than just suppressing appetite. It requires regular injections (every 3 days) and is most effective for individuals with significant diet-induced metabolic dysfunction.

Bariatric surgery (specifically Roux-en-Y Gastric Bypass and Sleeve Gastrectomy) is the most effective intervention for sustained weight loss and metabolic improvement, significantly altering gut microbiota diversity and reducing systemic inflammation.

Bariatric surgery, such as Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, offers the most significant and durable weight loss for severe obesity. It works by restricting stomach size and altering gut hormones and microbiota. Patients must commit to lifelong vitamin supplementation to prevent deficiencies.

In Heart Failure with Reduced Ejection Fraction (HFrEF), NuSH therapies show promise in reducing cardiovascular mortality and MACE, but require cautious patient selection and monitoring due to potential chronotropic effects (increased heart rate) and arrhythmia risks observed with earlier generation agents.

For heart failure with reduced ejection fraction (HFrEF), NuSH therapies are not yet a standard first-line treatment due to safety concerns like increased heart rate. However, recent real-world data suggests they may significantly reduce mortality in stable patients. If your doctor considers this, ensure you are clinically stable, have a normal resting heart rate, and are monitored closely. It is crucial to combine this therapy with resistance training and high protein intake to prevent muscle loss, which can be a side effect of rapid weight loss.

Tirzepatide may result in an increase in non-serious adverse events (risk ratio 1.33, 95% CI 1.03 to 1.71) compared to placebo.

Clinicians should monitor for non-serious adverse events when prescribing tirzepatide.

Specific gut microbial metabolites (SCFAs, Bile Acids, Tryptophan derivatives) stimulate GLP-1 secretion from intestinal L cells via specific receptors (FFAR2/3, TGR5, GPR142).

Consuming fiber (for SCFAs), specific fermented foods (for BAs), and tryptophan-rich foods can naturally boost GLP-1 by activating specific gut receptors. This supports metabolic and musculoskeletal health.

GLP-1 receptor agonists exert tissue-protective effects across multiple organs (pancreas, heart, liver, adipose, muscle, kidney, brain) primarily by driving mitochondrial remodeling, including improved biogenesis, quality control, and reduced oxidative stress.

GLP-1 medications (like semaglutide or liraglutide) do more than just help you lose weight; they actively improve the energy-producing centers (mitochondria) in your heart, liver, and other organs. This cellular repair helps protect these organs from damage, offering benefits that go beyond simple calorie reduction.

In pancreatic beta cells, GLP-1 receptor agonists directly protect against apoptosis and improve insulin secretion by enhancing mitochondrial ATP production, reducing oxidative stress, and promoting autophagy.

For people with Type 2 Diabetes, GLP-1 drugs help preserve the insulin-producing cells in the pancreas by keeping their energy factories (mitochondria) healthy and reducing cellular stress. This helps maintain the body's natural ability to produce insulin.

Incretin therapies could ameliorate fatty liver disease, chronic inflammation, sleep apnea, and possibly degenerative bone disorders and cognitive decline.

Incretin therapies may be considered for patients with these co-morbidities, pending further research.

GLP-1 receptor agonists exert direct antihypertensive effects independent of weight loss by modulating the sympathetic nervous system, improving endothelial function, enhancing renal sodium excretion, and suppressing the renin-angiotensin-aldosterone system.

Even without losing weight, GLP-1 medications help lower blood pressure by directly relaxing blood vessels, helping your kidneys excrete more sodium, and calming the nervous system signals that raise blood pressure. They also reduce the activity of hormones that constrict blood vessels.

Semaglutide likely results in little to no difference in quality of life with a mean difference of 2.12 (95% CI 0.95 to 3.28) in SF-36 physical functioning score at medium-term follow-up.

While semaglutide aids in weight loss, its impact on quality of life may be minimal.

By 2025, GLP-1RAs are anticipated to receive FDA approval for new indications including chronic kidney disease and heart failure.

Healthcare providers should stay informed about upcoming indications for GLP-1RAs to optimize treatment options.

Baseline disease severity, depressive symptoms, insulin resistance, and preperitoneal fat were negatively associated with PASI improvement.

Understanding these associations can help tailor treatment strategies for better outcomes.

A variety of clinical tools exist to assess nutritional status, sarcopenia, and physical frailty in liver transplant recipients.

Practitioners should utilize available assessment tools to evaluate frailty and nutritional status in liver transplant patients.

The use of safe and effective weight-loss medications may influence referral patterns for MBS in the future.

Practitioners should consider the evolving landscape of obesity treatment when referring patients for MBS.

Adverse events (AEs) were more common in the T2D group (78.3% vs. 50.0%).

Healthcare providers should monitor for gastrointestinal symptoms in T2D patients using tirzepatide.

In untrained older adults with adequate baseline protein intake (≥1.0 g/kg/day), consuming 40 g of protein either post-exercise or pre-sleep does not enhance resistance exercise training-induced improvements in muscle thickness or strength compared to resistance exercise training alone.

If you are an older adult (60+) who is new to resistance training and already eating at least 1.0 grams of protein per kilogram of body weight every day, you do not need to stress about drinking protein immediately after your workout or eating casein right before bed. Your muscles will grow and get stronger just from doing the resistance exercises consistently. Save your money and focus on eating enough protein throughout the day and sticking to your training schedule.

Hamstring hypertrophy plays a minimal role in strength transfer between the Nordic hamstring exercise (NHE) and the stiff-leg deadlift (SDL) in resistance-untrained individuals.

If you want to improve strength in both Nordic Hamstring Exercises and Stiff-Leg Deadlifts, do not rely on just one. Training one exercise will not significantly boost your strength in the other, even if you build muscle. To maximize strength across both knee-flexion and hip-extension movements, you must train both exercises within the same training block.